Kornimate/medical-research-clean huggingface dataset:
randomized trial of tapas acupressure for weight loss maintenance

Conditions: Obesity

Summary: this randomized clinical trial evaluates the efficacy of tat(tapas acupressure technique) compared to a social support (ss) group for the primary outcome of weight loss maintenance. we recruit obese adults from the kaiser permanente northwest managed care setting. those who meet eligibility criteria are entered into an intensive six-month weekly group-based behavioral weight loss program. those who meet threshold weight loss criteria (n=\~288) are randomly assigned to either tat instruction or social support group. participants in both groups attend the same schedule of group meetings with parallel contact hours. participants in the tat group are advised to practice the technique at home. participants are weighed and questionnaires administered at entry, randomization, and at 12 and 18 months post entry. the main outcome measure is weight at 18 months.


Eligibility criteria:
* inclusion criteria for the phase i weight loss program: * men and women * at least 30 years of age * bmi 30-50 kg/m2 (inclusive) * weight \<400 lbs * reside in portland metropolitan area including vancouver/clark county, washington * willing and able to participate in all aspects of the intervention * willing to attend the group-based weight loss program for 6 months * willing to follow a reduced calorie healthy dietary pattern * willing to exercise on a regular basis * willing to lose 10 pounds during the 6-month weight loss program * willing to accept random assignment to one of the two maintenance interventions * willing to provide informed consent exclusion criteria for the phase i weight loss program * medical conditions or treatments that would be contraindicated using a diet and exercise weight loss treatment * treatment for cancer (except for non-melanoma skin cancer) currently or in the past 2 years * diabetes treated with insulin; does not exclude diet-controlled, controlled with sulfonylurea (glyburide, glipizide, etc.) with primary physician's approval, or controlled with other oral agents (metformin, precose, glitazone.) * psychiatric hospitalization in past 2 years * conditions that require limitation of physical activity * congestive heart failure * cardiovascular disease (stroke, mi, cabg, angioplasty/stent) in the past 2 years * taking weight loss medications currently or within past 6 months * any history of weight loss surgery or scheduled surgery for weight loss. * liposuction in the past 12 months * prior acupuncture or acupressure treatments for weight loss * planning to leave the area prior to the end of the program * body weight change \> 20 pounds in the past 6 months * pregnant, breast feeding, or planning pregnancy prior to the end of participation * current participation in another clinical trial * investigator discretion for safety or adherence reasons * household member (living at the same address) of another participant in this study * life clinical trial staff member or family member of life trial staff person
long-term follow-up study of patients receiving atl001

Conditions: Melanoma; Advanced Non Small Cell Lung Cancer

Summary: this is an open-label, multi-centre phase ii study to evaluate the long-term safety and clinical activity of atl001, previously administered intravenously to patients in study atx-ns-001 (nct04032847) or study atx-me-001 (nct03997474).

up to 90 patients with advanced non-small cell lung cancer ( nsclc) or metastatic or recurrent melanoma will be enrolled after either: completing 2 years of follow-up visits in study atx-ns-001 or study atx-me-001; or voluntary withdrawal from these studies prior to the completion of the 2 year of follow-up period. each patient will be followed up for a minimum period of 5 years, or until death if sooner, in this long-term follow up protocol. for patients who are still alive after 5 years of follow-up, survival data will continue to be collected until the end of the study, which will occur when the last patient has completed 5 years of follow-up withdraws from study or has died.

Eligibility criteria:
inclusion criteria: 1. patients must have given written informed consent to participate in the study. 2. patients must have received atl001 in a previous clinical trial. 3. patients must be considered, in the opinion of the investigator, capable of complying with the protocol requirements. exclusion criteria: there are no exclusion criteria.
phase i/ib study of nis793 in combination with pdr001 in patients with advanced malignancies.

Conditions: Breast Cancer; Lung Cancer; Hepatocellular Cancer; Colorectal Cancer; Pancreatic Cancer; Renal Cancer

Summary: to characterize the safety and tolerability of nis793 as single agent and in combination with pdr001 and to identify recommended doses for future studies.


Eligibility criteria:
inclusion criteria: 1. written informed consent must be obtained prior to any screening procedures. 2. patient (male or female) ≥ 18 years of age. 3. escalation: patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by recist version 1.1 who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. 4. expansion: patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by recist version 1.1, who have progressed despite standard therapy following their last prior therapy or are intolerant to standard therapy and fit into one of the following groups: group 1: nsclc resistant to anti-pd-1/pd-l1; group 2: tnbc; group 3: hcc; group 4: mss-crc; group 5: pancreatic; group 6 ccrcc resistant to anti-pd-1/pd-l1. resistance to anti-pd-1/pd-l1 therapy is defined as: documented progressive disease occurring while on/or within 6 months after anti-pd-1 and/or anti-pd-l1 agent (single or combination) received as the last therapy prior to enrollment. 5. ecog performance status ≤ 2. 6. patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. patient must be willing to undergo a new tumor biopsy at screening, and during therapy on this study. exceptions may be made on a case by case basis after documented discussion with novartis. exclusion criteria: 1. history of severe hypersensitivity reactions to study treatment ingredients or other monoclonal antibodies and components of study drug. 2. patients with active, known or suspected autoimmune disease. note: patients with vitiligo, type i diabetes mellitus, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. 3. hiv infection. 4. active hbv or hcv infection. other protocol-defined inclusion/exclusion criteria may apply.
the relationship between driving pressure, mechanical power, oxygenation and saturation indices: retrospective observational study

Conditions: Acute Respiratory Distress Syndrome; Pneumonia

Summary: by using mechanical power and driving pressure instead of pmean we calculate new oxygen saturation indices like driving pressure oxygen index (oidp), dynamic power oxygen index (oimpdyn), total power oxygen index (oimptot), driving pressure saturation index (osidp), dynamic power saturation index (osimpdyn) ve power saturation index (osimptot). new oxygenation and saturation indices are able to predict icu mortality better than the conventional indexes and rates.


Eligibility criteria:
inclusion criteria: - patients with a diagnosis of covid-19 related acute respiratory syndrome (c-ards) which hospitalized in bakirköy dr. sadi konuk training and research hospital intensive care unit exclusion criteria: * patients who did not receive invasive mechanical ventilation support. * patients who stayed in the intensive care unit for less than 24 hours. * patients with missing data * patients who received mechanical ventilation support for less than 24 hours * patients with chronic obstructive pulmonary disease (copd). * patients with congestive heart failure * patients who underwent tube thoracostomy due to tension pneumothorax * patients who received extracorporeal membrane oxygenation (ecmo) support

Keywords: acute respiratory distress syndrome pneumonia oxygenation index saturation index
exploring the immunology of sarcoidosis

Conditions: Sarcoidosis

Summary: in sarcoidosis, over activity of parts of the immune system drives the accumulation of granulomas (collections of immune cells) in affected parts of the body. to facilitate development of effective and safe treatment options in the future it will be vital to understand how and why the immune system becomes over active. the aim of this research is to work towards this goal by studying cells of the immune system and the molecular pathways inside these cells that control how they behave. this will be achieved by analysing patterns of proteins and rna (the code used to tell cells which proteins to produce) in immune cells present in blood samples and tissue biopsies from people with sarcoidosis.


Eligibility criteria:
inclusion criteria: 1. males or females, of any race, between 18 and 85 years of age, inclusive 2. able to provide written informed consent 3. clinician diagnosis of sarcoidosis 4. treatment-naïve or receiving immunomodulatory therapy. exclusion criteria: 1. evidence of acute bacterial infection or other condition likely in the opinion of the investigator to significantly impact results of blood assays.

Keywords: macrophage lymphocyte cytokine immunology
treatment of postviral olfactory dysfunction

Conditions: Hyposmia

Summary: a decreased sense of smell (hyposmia) is often caused by viral infections, such as covid-19. today, the only recommended treatment for hyposmia is olfactory training, a time consuming method with limitations in terms of both compliance and effect. the aim of this study is therefore to evaluate, as well as optimize, a new treatment method for olfactory loss. hyposmic participants will be recruited and randomized into two different treatment conditions. one group will do regular olfactory training and the other will do passive olfactory training with scented nose plugs. the training will be conducted in the home of the individual monday through friday for two consecutive months. subjective and objectvie measures of olfactory problems will be assessed before and after treatment, as well as subjective measures related to quality of live and genereal wellbeing.


Eligibility criteria:
inclusion criteria: * 18 - 65 years old * physically and cognitively capable of participating in the study * having appropriate olfactory screening test scores (hyposmic) exclusion criteria: * anosmics * individuals with other diagnoses that could affect the study results
efficacy and safety of simtuzumab (sim) with folfiri as second line treatment in colorectal adenocarcinoma

Conditions: Colorectal Cancer

Summary: the primary objective of this study is to compare the additive efficacy of sim versus placebo in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (folfiri) as measured by improvement in progression-free survival (pfs) in participants with metastatic kras mutant colorectal adenocarcinoma who have progressed following a first-line oxaliplatin- and fluoropyrimidine-containing regimen.


Eligibility criteria:
inclusion criteria: * metastatic colorectal carcinoma with kras mutation * received first line therapy and discontinued part or all of first line therapy * estimated life expectancy \> 3 months * stage iv disease * eastern cooperative oncology group (ecog) performance status: 0-2 * adequate hepatic and hematologic function * no major operations within 4 weeks prior to treatment start exclusion criteria: * more than 1 prior chemotherapy regimen for stage 4 colorectal cancer * experimental medical treatment within 30 days prior to study entry * known or suspected cerebral metastases * history or presence of any form of cancer, other that colorectal cancer, within the 3 years prior to enrollment * known dihydropyrimidine dehydrogenase-deficiency (special screening not required) * subjects with angina pectoris, poorly controlled ventricular arrhythmias (does not include asymptomatic, occasional premature ventricular contractions), history of clinically significant coronary heart disease or cardiomyopathy, or electrocardiogram (ecg) abnormalities consistent with ischemia * uncontrolled hypertension (seated systolic blood pressure \> 180 mm hg or diastolic blood pressure \> 110 mm hg) at screening * clinically active liver disease, including active hepatitis (any etiology) or cirrhosis * anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 21 days prior to randomization * prior irinotecan therapy for metastatic disease is not permitted * systemic fungal, bacterial, viral, or other infection note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: gsi gilead gilead sciences gs-6624 colorectal cancer kras oncology monoclonal antibody
safety and efficacy study of an interactive wound dressing (kc002) for the treatment of diabetic foot ulcers

Conditions: Foot Ulcer; Diabetes

Summary: the objective of this study is to determine the safety and effectiveness of a device (the kc-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with type 1 or type 2 diabetes mellitus. this is a prospective, randomized, multi-center, unmasked, controlled study. all patients will receive care for the diabetic foot ulcer during the study. participation in the study is for 24 weeks.


Eligibility criteria:
inclusion criteria: participants included in the study must: * have type 1 or type 2 diabetes mellitus * have a diabetic foot ulcer on the bottom of the foot or heal which has been present for three (3) weeks but less than two (2) years and is sufficient size to qualify for the study * be able to visit the study doctor regularly for 24 weeks exclusion criteria: participants may not be included if: * the diabetic foot ulcer is infected * they have poor circulation in their study foot * cannot or will not wear a special boot to take pressure off the study ulcer * they have certain other diseases or laboratory values which are not within a specified range
predictive factors and outcome in medical thoracoscopy

Conditions: Pleuritis

Summary: retrospective survey for factors predicting the outcome of medical thoracoscopy

retrospective survey for factors predicting the outcome of medical thoracoscopy in patients with malignant pleuritis

Eligibility criteria:
inclusion criteria: * progressive malignancy * pleuritis exclusion criteria: * respiratory failure * unable to consent
exparel use in adductor canal block after total knee arthroplasty

Conditions: Arthritis Knee; Pain, Postoperative; Opioid Use

Summary: exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. the purpose of this study is to explore the effectiveness of exparel (liposomal bupivacaine) in adductor canal blocks for peri-operative pain control following a total knee arthroplasty (tka) procedure.

the effectiveness of an exparel block (bupivacaine liposomal injectable suspension) for post-operative pain control has been well studied with encouraging results. at the investigators' institution, exparel has been approved as a safe and effective option for use in shoulder surgeries and have had encouraging results in adductor canal use for pain control in patients undergoing tka. exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. the purpose of this study is to explore the effectiveness of exparel (liposomal bupivacaine) in adductor canal blocks (acb) for peri-operative pain control following a total knee arthroplasty (tka) procedure. specifically, the investigators look to see if exparel acb reduces opioid requirement use post-operatively, reduces pain scores post-operatively, provides earlier mobilization, and decreases length of hospital stay.

Eligibility criteria:
inclusion criteria: * patients were eligible for inclusion if they were undergoing unilateral primary tka for a diagnosis of knee osteoarthritis and were not undergoing any additional concomitant procedures were. exclusion criteria: * patients were not eligible for our study if they were undergoing revision tka, if they were undergoing bilateral tka or concomitant procedures, or if they had an active infection.

Keywords: exparel adductor knee arthroplasty opioid
low-dose interleukin-2 and rapamycin on sjögren's syndrome

Conditions: Sjögren's Syndrome

Summary: the purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose il-2 combined with rapamycin in the treatment of sjogren's syndrome

a randomized, open clinical trial was designed. patients will be randomly divided into three groups，including ld-il2 group, rapamycin group, ld-il2+rapamycin group. the improvement of clinical and laboratory indexes will be evaluated. changes of immune cell subsets and cytokines will be monitored.

Eligibility criteria:
inclusion criteria: 1. male or female, and aged 18-70 at the time of screening visit. 2. patients with sjogren's syndrome who meet the 2002 eular classification criteria. 3. if the standardized treatment is not effective or relapses, it is clinically necessary to give additional immunomodulatory treatment. 4. disease activity: essdai≥4 points. 5. the pregnancy test results of female subjects of childbearing age should be negative at screening and baseline. 6. the written informed consent form approved by the ethics committee of peking university people's hospital was signed and dated by the subject or legal representative. exclusion criteria: 1. severe chronic liver, kidney and heart dysfunction. 2. severe drug-resistant bacterial infections, such as bacteremia and septicemia. 3. patients with tumor and tumor history. 4. chronic respiratory failure. 5. patients who are ineffective in high-dose hormone pulse therapy. 6. those who use rituximab or other biological agents within 3 months. 7. patients with active tuberculosis infection or potential tuberculosis infection. 8. there are obstacles that can't cooperate or cause interference in completing this research: such as mental patients.
a research study looking at how nnc0385-0434 tablets work to lower blood cholesterol in people with heart disease or a high risk of heart disease

Conditions: Atherosclerotic Cardiovascular Disease

Summary: this study looks at how well a new medicine, nnc0385-0434, works to lower blood cholesterol levels. participants will either get nnc0385-0434 as a tablet (a potential new medicine), or placebo as a tablet (a dummy medicine that looks like nnc0385-0434 but has no effect on the body), or evolocumab as an injection (a medicine that doctors can already prescribe). which treatment participants get is decided by chance. if participants get nnc0385-0434 or placebo participants will need to take 1 tablet every morning. if participants get evolocumab participants will need to take 1 injection every 2 weeks. the study will last for about 22 weeks. about 255 people will participate in the study. participants will have 9 visits to the clinic and 2 phone calls with the study doctor. some people will be invited to participate in a sub-study and will have 4 extra visits (13 visits in total). participants will have blood samples taken at all visits to the clinic (except visit 0). at 4 clinic visits, participants will have an electrocardiogram (ecg). this is a test to check your heart. women can only take part in the study if they are not able to become pregnant.


Eligibility criteria:
inclusion criteria: * males or females of non-childbearing potential. * established atherosclerotic cardiovascular disease (ascvd) (criteria a) or ascvd risk (criteria b): 1. age 40 years or older at the time of signing informed consent and history of ascvd 2. age above 50 years at the time of signing informed consent and with ascvd risk * serum ldl-c above or equal to 1.8 mmol/l (above or equal to 70 mg/dl) as measured by the central laboratory at screening. * japanese participants: serum ldl-c above or equal to 2.6 mmol/l (above or equal to 100 mg/dl) for participants of 40 years of age or older and with a history of coronary heart disease, and serum ldl-c above or equal to 3.1 mmol/l (above or equal to 120 mg/dl) for all other japanese participants * participants must be on maximally tolerated dose of statins. * participants not receiving statin must have documented evidence of intolerance to all doses of at least two different statins. exclusion criteria: * treatment with pcsk9i therapy (alirocumab or evolocumab within 90 days prior to screening) or pcsk9 sirna therapy (inclisiran within 12 months prior to screening). * fasting triglyceride above 4.52 mmol/l (above 400 mg/dl) as measured by the central laboratory at screening. * myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening. * renal impairment with egfr less than 30 ml/min/1.73 m2 as measured by the central laboratory at screening
the effectiveness of a recovery program for people with mental illness.

Conditions: Mental Illness

Summary: recovery-oriented approach has been the main trend in mental health field. however, few recovery-oriented programs are available in taiwan, and many taiwanese people with mental illness don't understand the concepts of recovery. a program which provides recovery knowledge and assists in setting recovery goals is beneficial for taiwanese people with mental illness. hence, this study aimed to investigate the effectiveness of a recovery program for people with mental illness.

this is a randomized control trial. participants will be recruited from the psychiatric rehabilitation organizations in taiwan. they will be randomly assigned to the intervention group or control group. the recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. we will introduce concepts of recovery and personal strengths in phase 1. then, we will help participants to set goals and implement their plans in phase 2. participants will fill out five questionnaires during the recruitment meeting, including stages of recovery scale, medical outcomes study social support survey, the hope scale, rosenberg self-esteem scale and brief symptom rating scale-50. they will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. six months later, participants will receive a follow-up interview and fill out the questionnaires again. the control group will receive a spiritual book and complete the questionnaires at the same time as the intervention group.

Eligibility criteria:
inclusion criteria: * diagnosis of mental illness * lived in community exclusion criteria: -
counseling of pregnant women during corona

Conditions: Respiratory Tract Infections

Summary: corona virus is known as covid 19 and is transmitted through droplet infection

symptoms of corona include cough fever and dyspnea

Eligibility criteria:
inclusion criteria: * pregnant women exclusion criteria: * non pregnant women